• VistaGen Reports Positive New Data from AV-101, Probenecid Study americanpharmaceuticalreview
    September 07, 2020
    VistaGen Therapeutics announced positive new data from the Company's second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. Probenecid has extensive data supporting its safe oral delivery and ability to ...
PharmaSources Customer Service